Hims & Hers Health (NYSE:HIMS) Trading Up 11.4% – Time to Buy?

Hims & Hers Health, Inc. (NYSE:HIMS) rose 11.4% on Monday . The company traded as high as $29.69 and last traded at $29.8670. Approximately 10,285,276 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 30,489,139 shares. The stock had previously closed at $26.82.

Analyst Ratings Changes

Several research analysts have recently weighed in on HIMS shares. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Truist Financial upped their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research note on Friday, May 22nd. Barclays upped their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Finally, Morgan Stanley decreased their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Stock Performance

The company has a market capitalization of $6.83 billion, a PE ratio of -327.70, a PEG ratio of 50.32 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company has a 50 day moving average price of $25.41 and a 200 day moving average price of $26.75.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.20 earnings per share. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the transaction, the insider directly owned 299,368 shares in the company, valued at approximately $8,981,040. This represents a 3.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Capital World Investors raised its position in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the period. State Street Corp raised its holdings in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.